全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
Antibiotics  2013 

Prescriber and Patient Responsibilities in Treatment of Acute Respiratory Tract Infections — Essential for Conservation of Antibiotics

DOI: 10.3390/antibiotics2020316

Keywords: antibiotics, communication, primary care, resistance, symptomatic management, respiratory tract infection

Full-Text   Cite this paper   Add to My Lib

Abstract:

Inappropriate antibiotic use in normally self-limiting acute respiratory tract infections (RTIs), such as sore throat and the common cold, is a global problem and an important factor for increasing levels of antibiotic resistance. A new group of international experts—the Global Respiratory Infection Partnership (GRIP)—is committed to addressing this issue, with the interface between primary care practitioners and their patients as their core focus. To combat the overuse of antibiotics in the community, and facilitate a change from prescribing empiric antibiotic treatment towards cautious deferment combined with symptomatic relief, there is a need to introduce and enhance evidence-based dialogue between primary care practitioners and their patients. Communication with patients should focus on the de-medicalisation of self-limiting viral infections, which can be achieved via a coherent globally endorsed framework outlining the rationale for appropriate antibiotic use in acute RTIs in the context of antibiotic stewardship and conservancy. The planned framework is intended to be adaptable at a country level to reflect local behaviours, cultures and healthcare systems, and has the potential to serve as a model for change in other therapeutic areas.

References

[1]  ECDC/EMEA Joint Technical Report. The Bacterial Challenge: Time to React, Emea/576176/2009. .
[2]  Infectious Diseases Society of America. Facts about Antibiotic Resistance. April 2011. Available online: http://www.idsociety.org/IDSA/Site_Map/Topics_of_Interest/Antimicrobial_Resistance/Public_Policy/Facts_about_Antibiotic_Resistance.aspx (accessed on 20 March 2013).
[3]  Ho, J.; Tambyah, P.A.; Paterson, D.L. Multiresistant gram-negative infections: A global perspective. Curr. Opin. Infect. Dis 2010, 23, 546–553, doi:10.1097/QCO.0b013e32833f0d3e.
[4]  Nordmann, P.; Cuzon, G.; Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet. Infect. Dis. 2009, 9, 228–236, doi:10.1016/S1473-3099(09)70054-4.
[5]  Oteo, J.; Pérez-Vázquez, M.; Campos, J. Extended-spectrum beta-lactamase producing Escherichia coli: Changing epidemiology and clinical impact. Curr. Opin. Infect. Dis. 2010, 23, 320–326, doi:10.1097/QCO.0b013e3283398dc1.
[6]  Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America, the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society. Infect. Control Hosp. Epidemiol 2012, 33, 322–327, doi:10.1086/665010.
[7]  Chen, L.F.; Chopra, T.; Kaye, K.S. Pathogens resistant to antibacterial agents. Infect. Dis. Clin. North Am. 2009, 23, 817–845, doi:10.1016/j.idc.2009.06.002.
[8]  Falagas, M.E.; Rafailidis, P.I.; Matthaiou, D.K.; Virtzili, S.; Nikita, D.; Michalopoulos, A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents. 2008, 32, 450–454, doi:10.1016/j.ijantimicag.2008.05.016.
[9]  Bhutta, Z.A.; Rehan, A.; Zaidi, A.; St?lsby Lundborg, C. Newborn and young infant sepsis and antimicrobial resistance: Burden and implicationsAbstract. 2007. Available online: http://www.reactgroup.org (accessed on 19 March 2013).
[10]  National Collaborating Centre for Infectious Diseases. Proceedings of Community-Acquired Antimicrobial Resistance Consultation Notes, Winnipeg, MB, Canada, 10–11 February 2010; Available online: http://www.nccid.ca/files/caAMR_ConsultationNotes_final.pdf (accessed on 22 March 2013).
[11]  Goossens, H.; Ferech, M.; Vander Stichele, R.; Elseviers, M.; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005, 365, 579–587.
[12]  Centers for Disease Control and Prevention (CDC). Diseases/Pathogens associated with antimicrobial resistance. 2012. Available online: http://www.cdc.gov/drugresistance/ DiseasesConnectedAR.html (accessed on 22 March 2013).
[13]  Livermore, D.M. Current epidemiology and growing resistance of gram-negative pathogens. Korean J. Intern. Med. 2012, 27, 128–142, doi:10.3904/kjim.2012.27.2.128.
[14]  Paul, M.; Shani, V.; Muchtar, E.; Kariv, G.; Robenshtok, E.; Leibovici, L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob. Agents Chemother. 2010, 54, 4851–4863, doi:10.1128/AAC.00627-10.
[15]  Kollef, M.H. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front. Clin. Infect. Dis. 2008, 47, S3–S13, doi:10.1086/590061.
[16]  Drug Information System of the Netherlands’ Health Care Insurance Board (CVZ), GIP database. Available online: http://www.gipdatabank.nl (accessed on 9 May 2013).
[17]  Schito, G.C.; Naber, K.G.; Botto, H.; Palou, J.; Mazzei, T.; Gualco, L.; Marchese, A. The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 2009, 34, 407–413, doi:10.1016/j.ijantimicag.2009.04.012.
[18]  European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in EuropeAnnual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2011. Available online: http://www.ecdc.europa.eu/en/publications/Publications/ antimicrobial-resistance-surveillance-europe-2011.pdf (accessed on 9 May 2013).
[19]  World Health Organization. Factsheet No: 194: Antimicrobial resistance. March 2012. Available online: Http://www.Who.Int/mediacentre/factsheets/fs194/en/# (accessed on 15 March 2013).
[20]  World Health Organization. The evolving threat of antimicrobial resistance—Options for action. 2012. Available online: http://www.who.int/patientsafety/implementation/amr/publication/en/ (accessed on 15 March 2013).
[21]  Riedel, S.; Beekmann, S.E.; Heilmann, K.P.; Richter, S.S.; Garcia-de-Lomas, J.; Ferech, M.; Goosens, H.; Doern, G.V. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 2007, 26, 485–490, doi:10.1007/s10096-007-0321-5.
[22]  Bergman, M.; Huikko, S.; Pihlajam?ki, M.; Laippala, P.; Palva, E.; Huovinen, P.; Sepp?l?, H.; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997–2001. Clin. Infect. Dis. 2004, 38, 1251–1256, doi:10.1086/383309.
[23]  European Centre for Disease Prevention and Disease Control. Surveillance report. Surveillance of antimicrobial consumption in Europe. 2010. Available online: http://www.ecdc.europa.eu/en/ publications/Publications/antimicrobial-antibiotic-consumption-ESAC-report-2010-data.pdf (accessed on 11 March 2013).
[24]  Bronzwaer, S.L.; Cars, O.; Buchholz, U.; M?lstad, S.; Goettsch, W.; Veldhuijzen, I.K.; Kool, J.L.; Sprenger, M.J.; Degener, J.E.; European Antimicrobial Resistance Surveillance System. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis. 2002, 8, 278–282, doi:10.3201/eid0803.010192.
[25]  Costelloe, C.; Metcalfe, C.; Lovering, A.; Mant, D.; Hay, A.D. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis. Br. Med. J. 2010, 340, c2096, doi:10.1136/bmj.c2096.
[26]  Ndip, R.N.; Ntiege, E.A.; Ndip, L.M.; Nkwelang, G.; Akoachere, J.F.; Akenji T, N. Antimicrobial resistance of bacterial agents of the upper respiratory tract of school children in Buea, Cameroon. J. Health Popul. Nutr. 2008, 26, 397–404.
[27]  Appelbaum, P.C. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin. Infect. Dis. 2002, 34, 1613–1620.
[28]  Altiner, A.; Brockmann, S.; Sielk, M.; Wilm, S.; Wegscheider, K.; Abholz, H.H. Reducing antibiotic prescriptions for acute cough by motivating GPs to change their attitudes to communication and empowering patients: A cluster-randomized intervention study. J. Antimicrob. Chemother. 2007, 60, 638–644, doi:10.1093/jac/dkm254.
[29]  Australia National Prescribing Service. Press release. 1 in 5 Australians expect antibiotics for coughs or colds: New NPS campaign. Available online: http://www.nps.org.au/media-centre/media-releases/repository/1-in-5-australians-expect-antibiotics-for-coughs-or-colds-new-nps-campaign (accessed on 19 March 2013).
[30]  Special Eurobarometer 338. Antimicrobial resistance. Survey carried out by TNS Opinion & Social at the request of the Directorate-General for Health and Consumers. 2010. Available online: http://ec.europa.eu/health/antimicrobial_resistance/docs/ebs_338_en.pdf (accessed on 8 May 2013).
[31]  Francis, N.A.; Butler, C.C.; Hood, K.; Simpson, S.; Wood, F.; Nuttall, J. Effect of using an interactive booklet about childhood respiratory tract infections in primary care consultations on reconsulting and antibiotic prescribing: A cluster-randomised controlled trial. Br. Med. J. 2009, 339, b2885.
[32]  Little, P.; Gould, C.; Williamson, I.; Warner, G.; Gantley, M.; Kinmonth, A.L. Reattendance and complications in a randomised trial of prescribing strategies for sore throat: The medicalising effect of prescribing antibiotics. Br. Med. J. 1997, 315, 350–352, doi:10.1136/bmj.315.7104.350.
[33]  National Institute for Health and Clinical Excellence (NICE). Clinical guideline 69. Respiratory tract infections—Antibiotic prescribing. Prescribing of antibiotics for self-limiting respiratory tract infections and in adults and children in primary care. July 2008. Available online: http://www.nice.org.uk/nicemedia/live/12015/58249/58249.pdf (accessed on 18 March 2013).
[34]  Thamlikitkul, V.; Apisitwittaya, W. Implementation of clinical practice guidelines for upper respiratory infection in Thailand. Int. J. Infect. Dis. 2004, 8, 47–51, doi:10.1016/j.ijid.2003.09.001.
[35]  Gjelstad, S.; Straand, J.; Dalen, I.; Fetveit, A.; Str?m, H.; Lindb?k, M. Do general practitioners’ consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J. Antimicrob. Chemother. 2011, 66, 2425–2433, doi:10.1093/jac/dkr295.
[36]  Mazzaglia, G.; Caputi, A.P.; Rossi, A.; Bettoncelli, G.; Stefanini, G.; Ventriglia, G.; Nardi, R.; Brignoli, O.; Cricelli, C. Exploring patient- and doctor-related variables associated with antibiotic prescribing for respiratory infections in primary care. Eur. J. Clin. Pharmacol. 2003, 59, 651–657, doi:10.1007/s00228-003-0669-0.
[37]  Van Driel, M.L.; de Sutter, A.; Deveugele, M.; Peersman, W.; Butler, C.C.; de Meyere, M.; de Maeseneer, J.; Christiaens, T. Are sore throat patients who hope for antibiotics actually asking for pain relief? Ann. Fam. Med. 2006, 4, 494–499, doi:10.1370/afm.609.
[38]  Scott, J.G.; Cohen, D.; DiCicco-Bloom, B.; Orzano, A.J.; Jaen, C.R.; Crabtree, B.F. Antibiotic use in acute respiratory infections and the ways patients pressure physicians for a prescription. J. Fam. Pract. 2001, 50, 853–858. Erratum in: J. Fam. Pract. 2001, 50, 1077.
[39]  Altiner, A.; Haag, H.; Schraven, C.; Sensen, A.; Wilm, S.; Sandquist, S.; Esser, A.; Schlipper, A.; Abholz, H.H. Akuter Husten: Was erwarten die Patienten? Acute cough: What do patients expect? Z. Allg. Med. 2002, 78, 19–22.
[40]  Altiner, A.; Knauf, A.; Moebes, J.; Sielk, M.; Wilm, S. Acute cough: A qualitative analysis of how GPs manage the consultation when patients explicitly or implicitly expect antibiotic prescriptions. Fam. Pract. 2004, 21, 500–506, doi:10.1093/fampra/cmh505.
[41]  Welschen, I.; Kuyvenhoven, M.; Hoes, A.; Verheij, T. Antibiotics for acute respiratory tract symptoms: Patients’ expectations, GPs’ management and patient satisfaction. Fam. Pract. 2004, 21, 234–237, doi:10.1093/fampra/cmh303.
[42]  Infectious Diseases Society of America (IDSA). The 10×'20 initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 2010, 50, 1081–1083.
[43]  Boucher, H.W.; Talbot, G.H.; Benjamin, D.K., Jr.; Bradley, J.; Guidos, R.J.; Jones, R.N.; Murray, B.E.; Bonomo, R.A.; Gilbert, D. 10×'20 progress—Development of new drugs active against gram-negative bacilli: An update from the infectious diseases society of america. Clin. Infect. Dis. 2013, 56, 1685–1694.
[44]  Davies, S.C.; Fowler, T.; Watson, J.; Livermore, D.M.; Walker, D. Annual Report of the Chief Medical Officer: Infection and the rise of antimicrobial resistance. Lancet 2013, 381, 1606–1609.
[45]  Huttner, B.; Goossens, H.; Verheij, T.; Harbarth, S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect. Dis. 2010, 10, 17–31, doi:10.1016/S1473-3099(09)70305-6.
[46]  Mazińska, B.; Hryniewicz, W. European Antibiotic Awareness Day educational campaign—Has it changed public attitudes to antibiotic use in Poland? Pol. Merkur. Lekarski 2010, 29, 296–303.
[47]  Sabuncu, E.; David, J.; Bernède-Bauduin, C.; Pépin, S.; Leroy, M.; Bo?lle, P.Y.; Watier, L.; Guillemot, D. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. PLoS Med. 2009, 6, e1000084, doi:10.1371/journal.pmed.1000084.
[48]  Van der Velden, A.W.; Pijpers, E.J.; Kuyvenhoven, M.M.; Tonkin-Crine, S.K.; Little, P.; Verheij, T.J. Effectiveness of physician-targeted interventions to improve antibiotic use for respiratory tract infections. Br. J. Gen. Pract. 2012, 62, e801–e807, doi:10.3399/bjgp12X659268.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133